How Pharma IT Teams Can Achieve Continuous GxP Compliance and Audit Readiness

For most pharmaceutical IT leaders, compliance has become a permanent background hum of pressure. Somewhere across your estate, a manufacturing floor, a QC lab, a packaging line, a remote site, a regulated system needs to prove, on any given day, that it is exactly as controlled and documented as your SOPs claim. And increasingly, the honest answer to “can we prove that right now?” is “give us a few weeks to prepare.” 

That gap between everyday reality and inspection-day readiness is where risk lives. This blog looks at why that gap persists, what’s changing in the regulatory landscape, and how leading teams are closing it for good. 

The real problem: Compliance is breaking at the system level 

Talk to Manufacturing IT, Site IT, and CSV teams and a consistent picture emerges. Compliance isn’t failing because people don’t understand the regulations. It’s failing because the operating model can’t keep pace with digital complexity. 

Consider how most GxP compliance is actually maintained today. Endpoint configurations are hardened manually. Policy checks happen periodically. Evidence is assembled ahead of an audit rather than captured continuously. Ownership is split across Quality, IT, and Operations, so no single function owns the end-to-end outcome. The result is a model that is reactive by design, issues surface during audits instead of being prevented in real time. 

The endpoint estate is where this shows up most sharply. The thousands of end-user computing devices supporting regulated processes represent one of the largest uncontrolled risk surfaces in a pharma environment. Each one depends on local IT execution for OS hardening, access restrictions, and policy enforcement, which means thousands of potential points where configuration can quietly drift out of step with documentation. Something as routine as an engineer relaxing a control to troubleshoot an issue, and forgetting to restore it, can create a compliance deviation that goes undetected until an inspector finds it. 

Layer on legacy and non-connected systems, still common across manufacturing and plant floors, and the challenge compounds. These are precisely the devices hardest to monitor consistently, yet they often run the most critical applications. 

The industry perspective: The bar is rising, not holding 

None of this would matter as much if regulators were standing still. They aren’t. 

FDA enforcement has accelerated markedly, with drug warning letters climbing to roughly 303 in FY2025, up from 190 the year before. And when you read those letters back-to-back, the findings are strikingly consistent: unreliable records, retrospective edits, weak access controls, disabled or unreviewed audit trails, and — underneath it all — the same SOP applied differently from one site to the next. Quality-system failures now account for over 30% of recent citations, and data integrity remains the single most cited theme, appearing in an estimated 60–80% of drug GMP warning letters. 

The strategic message for IT leaders is clear. Inspectors are no longer treating compliance as a documentation exercise. They expect every result that supports a quality decision to be attributable, complete, and demonstrable at the moment it’s created, not reconstructed later. That is a fundamental shift from “inspection prep” to “always-ready.” 

The stakes justify the scrutiny. Roughly half of global drug recalls are linked to GxP lapses, and the downstream cost is severe: recalls routinely run into the millions per event, while McKinsey estimates that manufacturing halts and supply-chain disruptions can erase around 25% of earnings over a decade. Compliance, in other words, has quietly become a business-continuity and revenue-protection concern, not a departmental checklist. 

This is why forward-looking manufacturers are reframing the goal. Instead of asking “how do we pass the next audit?” they’re asking “how do we make our environment continuously prove its own compliance?” 

The direction of travel: From audit-driven to system-driven 

Closing the readiness gap doesn’t require heroics from IT teams. It requires shifting the burden of compliance from people to the system itself. A few principles are emerging among teams making the most progress: 

• Enforce controls automatically, not manually. When hardening policies are applied and locked at the endpoint — and automatically restored after legitimate troubleshooting — configuration drift stops being an inevitability. 

• Make evidence continuous, not periodic. Daily, role-based compliance reporting means audit readiness becomes a live state rather than a scramble, and deviations surface early enough to remediate before they become findings. 

• Cover the whole estate, including legacy and offline devices. Continuous compliance only works if it reaches the systems that are hardest to manage, not just the easy, connected ones. 

• Centralize oversight, reduce local dependency. Removing reliance on local expertise for routine compliance tasks eliminates a major source of inconsistency across sites and geographies. 

This is where a purpose-built approach earns its place. ignio™ AI.Digital Workspace applies exactly these principles to the regulated endpoint estate automatically enforcing and restoring hardening controls, generating daily compliance evidence, and extending coverage to legacy and offline devices so GxP readiness becomes a property of the system rather than a task for the team. It’s less about the technology itself and more about the operating-model shift it unlocks: from reactive, human-driven, audit-season compliance to a posture that is built-in and continuously demonstrable. 

For pharma IT teams under mounting pressure, that shift is fast becoming the difference between chasing readiness and simply having it. 

Curious how continuous compliance would apply to your endpoint estate? That’s a conversation worth having before the next inspection window not during it – Request a Demo.